Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
FDA clears belzutifan-pembrolizumab combination to delay kidney cancer's return

FDA clears belzutifan-pembrolizumab combination to delay kidney cancer's return

New Capabilities

A two-drug regimen becomes a new post-surgery option for high-risk clear cell kidney cancer

Today: FDA approves the belzutifan-pembrolizumab combination

Overview

Surgery removes the tumor. For many high-risk kidney cancer patients, it doesn't end the disease. On June 12, 2026, the U.S. Food and Drug Administration (FDA) approved pairing belzutifan with the immunotherapy pembrolizumab to keep these patients cancer-free for longer after their kidney is removed.

The approval rests on a 1,841-patient trial. Adding belzutifan to pembrolizumab cut the risk of the cancer returning or death by 28% compared with pembrolizumab alone. The benefit came with more side effects, so doctors now weigh longer disease control against higher toxicity.

Why it matters

For high-risk kidney cancer patients, surgery often isn't the end. This regimen lowers the odds the cancer comes back.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

1,841
Patients in the trial
All had clear cell kidney cancer removed by surgery and a high risk of recurrence.
28%
Lower risk of recurrence or death
Reduction with the combination versus pembrolizumab alone.
0.72
Hazard ratio for disease-free survival
Below 1.0 means the combination delayed recurrence; the result was statistically significant.
52.1%
Serious side-effect rate
Grade 3 or worse treatment-related events on the combination, versus 30.2% on pembrolizumab alone.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 3 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

August 2021 June 2026

4 events Latest: Today
Tap a bar to jump to that date
  1. FDA approves the belzutifan-pembrolizumab combination

    Today Approval

    Drawing on the 1,841-patient LITESPARK-022 trial first reported at the 2026 ASCO genitourinary cancers meeting, the FDA clears the combination to delay recurrence after surgery.

  2. Belzutifan approved for advanced kidney cancer

    Approval

    The FDA expands belzutifan to patients with advanced clear cell kidney cancer whose disease progressed after earlier treatment.

  3. Pembrolizumab becomes a post-surgery standard

    Approval

    Based on the KEYNOTE-564 trial, the FDA approves pembrolizumab alone after kidney removal for high-risk patients. It later showed patients lived longer.

  4. Belzutifan wins its first approval

    Approval

    The FDA clears belzutifan for tumors tied to von Hippel-Lindau disease. It is the first drug to block the HIF-2-alpha protein, a target long thought undruggable.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

November 2017

Adjuvant sunitinib approval (2017)

The FDA approved sunitinib after surgery for high-risk kidney cancer based on the S-TRAC trial. The drug delayed recurrence but never showed patients lived longer. Side effects were heavy.

Then

Many oncologists hesitated to prescribe it. Adoption stayed low despite the approval.

Now

It became a cautionary case that a delay in recurrence does not always translate into longer life or wide use.

Why this matters now

It shows why the pending survival data for belzutifan-pembrolizumab matters so much. A recurrence benefit alone may not be enough to win over doctors.

November 2021

Adjuvant pembrolizumab approval (2021)

The FDA approved pembrolizumab alone after surgery for high-risk kidney cancer, based on the KEYNOTE-564 trial. Years later, follow-up showed patients on the drug lived longer than those on placebo.

Then

It became the first post-surgery treatment to gain traction in kidney cancer in years.

Now

It set the survival benchmark and the backbone that newer combinations, including this one, are built on.

Why this matters now

The new combination adds belzutifan to this exact drug. Its value depends on beating pembrolizumab alone, the standard it builds on.

August 2021

Belzutifan drugs an 'undruggable' target (2021)

The FDA approved belzutifan for tumors tied to von Hippel-Lindau disease. It was the first drug to block HIF-2-alpha, a protein that drives clear cell kidney cancer and was long considered impossible to target with a pill.

Then

It gave patients with a rare inherited cancer syndrome a non-surgical option.

Now

It opened a new line of attack on kidney cancer that Merck has since tested across multiple settings.

Why this matters now

This combination pushes that mechanism into earlier, more common disease, pairing it with immunotherapy right after surgery.

Sources

(6)